826 reports of this reaction
2.4% of all EXTENDED PHENYTOIN SODIUM reports
#7 most reported adverse reaction
HEADACHE is the #7 most commonly reported adverse reaction for EXTENDED PHENYTOIN SODIUM, manufactured by Viatris Specialty LLC. There are 826 FDA adverse event reports linking EXTENDED PHENYTOIN SODIUM to HEADACHE. This represents approximately 2.4% of all 34,830 adverse event reports for this drug.
Patients taking EXTENDED PHENYTOIN SODIUM who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for EXTENDED PHENYTOIN SODIUM, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for EXTENDED PHENYTOIN SODIUM:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 826 FDA reports for EXTENDED PHENYTOIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.4% of all adverse event reports for EXTENDED PHENYTOIN SODIUM, making it a notable side effect.
If you experience headache while taking EXTENDED PHENYTOIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.